Comprehensive impact of <i>PPARG</i> mutations in familial partial lipodystrophy type 3: Diagnosis, therapeutic strategies

This article reviews a paper in the <i>World Journal of Diabetes</i>. The study uncovers the link between <i>PPARG</i> gene mutations and metabolic disorders, such as insulin resistance, diabetes, and hypertriglyceridemia, and emphasizes the crucial role of genetic testing in precise diagnosis and personalized treatment. This article further points out that in-depth investigation into the clinical heterogeneity of <i>PPARG</i> mutations and their underlying mechanisms can contribute to optimizing management strategies. Meanwhile, the development of more effective targeted therapies and the conduct of extensive genomic research are of great significance for understanding familial partial lipodystrophy type 3 and related metabolic syndromes.